Medical and societal consequences of late presentation

Antiviral Therapy

Volumn 15, Issue SUPPL. 1, 2010, Pages 9-15

  Moreno, Santiago ^a   Mocroft, Amanda ^b   Monforte, Antonella D'Arminio ^c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c SAN PAOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; LOPINAVIR; RITONAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; DIARRHEA; DRUG SAFETY; ECONOMIC EVALUATION; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LIVER TOXICITY; LONG TERM CARE; MORTALITY; NAUSEA; PANCREATITIS; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; VIRUS LOAD; VIRUS TRANSMISSION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HIV-1; HUMANS; RISK FACTORS; TIME FACTORS;

EID: 77952032481     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1523     Document Type: Review

References (57)

1. Girardi E, Sabin CA, Monforte AD. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007; 46 Suppl 1:S3-S8. (Pubitemid 47312320)
2. Sabin CA, Smith CJ, Gumley H, et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004; 18:2145-2151. (Pubitemid 39463679)
3. Johnson M, Sabin C, Girardi E. Definition and epidemiology of late presentation in Europe. Antivir Ther 2010; 15 Suppl 1:3-8.
4. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
5. When To Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
6. Gill J, May M, Lewden C, et al. Causes of death in patients treated with ART, 1996 to 2006: collaborative analysis of 13 cohort studies. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 708.
7. Marcellin F, Abe C, Loubiere S, et al. Delayed first consultation after diagnosis of HIV infection in Cameroon. AIDS 2009; 23:1015-1019.
8. Lucas SB, Curtis H, Johnson MA. National review of deaths among HIV-infected adults. Clin Med 2008; 8:250-252. (Pubitemid 351960975)
9. Lanoy E, Mary-Krause M, Tattevin P, et al. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther 2007; 12:89-96. (Pubitemid 46340430)
10. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS 2006; 20:2371-2379.
11. Delpierre C, Lauwers-Cances V, Pugliese P, et al. Characteristics trends, mortality and morbidity in persons newly diagnosed HIV positive during the last decade: the profile of new HIV diagnosed people. Eur J Public Health 2008; 18:345-347. (Pubitemid 351786632)
12. Jensen-Fangel S, Pedersen L, Pedersen C, et al. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS 2004; 18:89-97. (Pubitemid 38402322)
13. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129. (Pubitemid 34786200)
14. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-2577. (Pubitemid 33096808)
15. Marin B, Thiebaut R, Rondeau V, et al. Association between CD4 and HIV RNA with non AIDS-related causes of death in the era of combination antiretroviral therapy. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract WEPEB019.
16. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22:2143-2153.
17. The Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
18. BHIVA. Audit of mortality 2005-2006. (Accessed 22 November 2009.) Available from http://bhiva.org/documents/ClinicalAudit/FindingsandReports/ MortalityAudit.ppt#1
19. Chadborn TR, Baster K, Delpech VC, et al. No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). AIDS 2005; 19:513-520. (Pubitemid 40515855)
20. Sobrino-Vegas P, Garcia-San ML, Caro-Murillo AM, et al. Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res 2009; 7:224-230.
21. Smit C, Hallett TB, Lange J, Garnett G, de Wolf F. Late entry to HIV care limits the impact of anti-retroviral therapy in the Netherlands. PLoS ONE 2008; 3:e1949. (Pubitemid 351984397)
22. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-1144.
23. Reekie J, Mocroft A, Engsig F, et al. Relationship between current level of immunodeficiency and non-AIDS defining malignancies. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 860a.
24. Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 2003; 32:527-533. (Pubitemid 36423125)
25. Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and non-fatal non-AIDS-defining illnesses in Europe. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 707.
26. Rockstroh JK, Gatell J, Landman R, Antinori A. Management of late-presenting patients with HIV infection. Antivir Ther 2010; 15 Suppl 1:25-30.
27. Smith CJ, Olsen CH, Mocroft A, et al. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. AIDS 2008; 22:47-56. (Pubitemid 350294877)
28. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32:48-56. (Pubitemid 36091484)
29. Curkendall SM, Richardson JT, Emons MF, Fisher AE, Everhard F. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2007; 8:483-490. (Pubitemid 47616826)
30. DeJesus E, Ortiz M, Khanlou H. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV treatment-naive HIV-1-infected patients at week 48: ARTEMIS. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 17-20 September 2007, Chicago, IL, USA. Abstract H-718b.
31. Kelleher T, Cross A, Dunkle L. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine. Clin Ther 1999; 21:1182-1192. (Pubitemid 29380473)
32. Moore RD, Keruly JC, Chaisson RE. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS 2001; 15:617-620.
33. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998; 91:301-308.
34. Uy J, Yang R, Thiry A, et al. Efficacy and safety by baseline HIV-RNA and CD4 count in treatment-naive patients treated With atazanavir/r and lopinavir/r in the CASTLE study. J Int AIDS Soc 2008; 11 Suppl 1:P8.
35. Jerico C, Knobel H, Montero M, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 2005; 28:132-137. (Pubitemid 40095795)
36. Hansel A, Bucher HC, Nuesch R, Battegay M. Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naive HIV-infected patients. J Acquir Immune Defic Syndr 2001; 26:191-193. (Pubitemid 32224193)
37. Mocroft A, Phillips AN, Soriano V, et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005; 21:743-752. (Pubitemid 41434178)
38. Vo TT, Ledergerber B, Keiser O, et al. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008; 197:1685-1694.
39. Mussini C, Manzardo C, Johnson M, et al. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS 2008; 22:2461-2469.
40. Robbins GK, Spritzler JG, Chan ES, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009; 48:350-361.
41. Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370:407-413. (Pubitemid 47176633)
42. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-410.
43. Battegay M, Nuesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006; 6:280-287.
44. Brogly SB, Bruneau J, Lamothe F, Vincelette J, Franco EL. HIV-positive notification and behavior changes in Montreal injection drug users. AIDS Educ Prev 2002; 14:17-28. (Pubitemid 34208838)
45. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006; 20:1447-1450. (Pubitemid 43948252)
46. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
47. Sullivan AK, Curtis H, Sabin CA, Johnson MA. Newly diagnosed HIV infections: review in UK and Ireland. BMJ 2005; 330:1301-1302. (Pubitemid 40813561)
48. Bunnell R, Ekwaru J, King R, et al. 3-year follow-up of sexual behaviour and HIV transmission risk of patients taking ART in rural Uganda. 15th Conference on Retroviruses and Opportunistic Infections 3-6 February 2008, Boston, MA, USA. Abstract 29.
49. Yazdanpanah Y, Lange J, Gerstoft J, Cairns G. Earlier testing for HIV - how do we prevent late presentation? Antvir Ther 2010; 15 Suppl 1:17-24.
50. Hamers FF, Phillips AN. Diagnosed and undiagnosed HIV-infected populations in Europe. HIV Med 2008; 9 Suppl 2:6-12.
51. Fakoya I, Reynolds R, Caswell G, Shiripinda I. Barriers to HIV testing for migrant Black Africans in Western Europe. HIV Med 2008; 9 Suppl 2:23-25. (Pubitemid 351819092)
52. Terence Higgins Trust. Criminalisation of HIV transmission in Europe: a rapid scan of the laws and rates of prosecution for HIV transmission within signatory States of the European Convention of Human Rights. (Updated June 2005. Accessed 26 June 2009.) Available from http://www.gnpplus.net/criminalisation/ index.shtml
53. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection. HIV Med 2004; 5:93-98.
54. Krentz HB, Gill MJ. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006. HIV Med 2008; 9:721-730.
55. Bucher HC, Bischof M, Brogan A, et al. Cost-effectiveness of firstline antiretroviral backbone therapies in combination with efavirenz in HIV-infected patients in Switzerland. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19-22 July 2009, Cape Town, South Africa. Abstract MOPED013.
56. Sanders GD, Bayoumi AM, Sundaram V, et al. Costeffectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005; 352:570-585. (Pubitemid 40204670)
57. Sterne JA. When should HIV-1-infected persons initiate ART? Collaborative analysis of HIV cohort studies. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 72LB.